ACDN-01 for stargardt disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 11 Jun 2024: Trial started, NCT06467344
  2. 21 Jun 2024: Trial registered, NCT06467344

The trials

NCT06467344: Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

State
Under way
Phase
Phase 1 and Phase 2
People
15 planned
Started
11 Jun 2024
Primary completion
1 Aug 2030
Arms
Low dose of ACDN-01, Mid-dose of ACDN-01, High dose of ACDN-01
Results
None posted
  1. 11 Jun 2024: Trial started
  2. 21 Jun 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.